Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, has appointed Michael Klichinsky, PharmD, PhD, as chief scientific officer.   Klichinsky co-founded the company in 2016 following his foundational work at the University of Pennsylvania that led to the development of Carisma’s chimeric antigen receptor macrophage (CAR-M) technology.   “The entire Carisma team is thrilled and honored to have Mike ...